| Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript | 11/05 20:39 | seekingalpha.com |
| Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates | 11/05 18:10 | zacks.com |
| Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update | 11/05 16:01 | prnewswire.com |
| Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024 | 11/05 09:01 | prnewswire.com |
| Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting | 11/05 09:00 | prnewswire.com |
| Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting | 11/05 09:00 | prnewswire.com |
| Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ | 11/04 16:01 | prnewswire.com |
| Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | 11/01 16:05 | prnewswire.com |
| Syndax Announces Participation in November Investor Conferences | 11/01 07:00 | prnewswire.com |
| Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024 | 10/29 07:00 | prnewswire.com |